Storage of Active Pharmaceutical Ingredients: GMP Safety and Compliance

In the Life Science sector, logistics is not an ancillary activity, but an essential element in ensuring the quality and safety of medicines along the supply chain.

In particular, the storage of active pharmaceutical ingredients (APIs) is a delicate phase, in which safety, control and regulatory compliance are essential to ensure the quality of the final product.

In fact, variations in temperature, humidity or environmental exposure can compromise the stability of an active ingredient. For this reason, API management requires specialized infrastructure and processes controlled according to Good Manufacturing Practice (GMP).

At Logistic Company, storage is therefore treated as a direct extension of the production process: each pharmaceutical API is stored in qualified environments, constantly monitored and managed according to international standards, in order to preserve its chemi-physical integrity and therapeutic efficacy.

Active pharmaceutical ingredients, or APIs (Active Pharmaceutical Ingredients), are the pharmacologically active substances responsible for the therapeutic effect of a medicine. Their quality directly influences the efficacy and safety of the medicine.

For this reason, APIs must be managed very carefully throughout the supply chain. They are sensitive to factors such as light, heat and humidity, and their storage conditions must be fully traceable, from receipt to storage to shipment and , then, to the production facility of the finished products.

Pharmaceutical logistics is not limited to transportation, but includes the complete management of raw materials as well.

Each phase is precisely planned and controlled:

1. Reception: verification of the quality and quantity of the active ingredients upon arrival.
2. Storage: maintenance under controlled conditions (e.g.: refrigeration for thermolabile drugs)
3. Internal transport: safe handling within warehouses or production sites.
4. Distribution: delivery to pharmaceutical manufacturing facilities or distributors.

Elements such as chemical stability, shelf life and sensitivity of the active pharmaceutical ingredient guide all operational decisions, from reception to storage to distribution, reducing the risks of alteration or contamination.

As far as the storage of active pharmaceutical ingredients is concerned, this phase requires infrastructures designed according to strict criteria. In fact, the suitable environment must assured:

• Areas separated by type and condition of the material
• Controlled layout
• HVAC Systems for Environmental Control
• Continuous monitoring of temperature and humidity

The traceability of raw materials is also a fundamental requirement. Each component of each batch (e.g. each pallet) is recorded with information on supplier, production date, entry date, expiry date, status and position within the warehouse.

Moreover, FIFO and FEFO logics ensure proper stock turnover, while SOPs (Standard Operating Procedures) govern every operational phase, from receipt to shipment.

All these procedures are supervised by a Quality system based on GMP, with periodic audits by health authorities (e.g., AIFA for Italy, FDA for the USA) to ensure the compliance.

One of the critical aspects in the storage of active pharmaceutical ingredients is the management of the quarantine of materials.

Each batch of API is immediately identified and segregated in dedicated areas, where it remains in quarantine until release, authorization for use by the responsible Qualified Person. No material may be used in manufacture prior to formal approval.

This approach guarantees maximum transparency and full documentary control, essential elements during GMP inspections conducted by regulatory bodies, such as AIFA.

In the storage of active pharmaceutical ingredients, the post-quarantine phase is represented by the change of status.

Once the required checks have been completed and the qualified person has been released, the API can be transferred from the “quarantine” state to the “approved” state, which is available for use.

Any change in status is authorized exclusively through validated management systems, which record every single operation in compliance with GMP procedures.

This ensures continuity and full traceability within the storage process, which is one of the most critical elements during audits and regulatory inspections.

All activities related to the storage of active pharmaceutical ingredients, including quarantine management and change of status of medicines, can only be carried out within sites authorized and inspected by the competent authorities, such as, for example, AIFA.

Relying on an AIFA authorized warehouse therefore means complying not only with structural requirements, but also with a rigorous Quality system, based on operating procedures, quality control and document traceability, fully compliant with the requirements dictated by Good Manufacturing Practice (GMP).

It is therefore an integrated model that guarantees product safety at a fundamental stage throughout the supply chain. For pharmaceutical companies, this is a key element in choosing a logistics partner that specializes in the storage of active pharmaceutical ingredients.

In this regulated and highly structured context, the effectiveness of the storage of active pharmaceutical ingredients depends on the ability to maintain optimal environmental conditions and comply with international guidelines, mainly GMP standards.

Logistic Company’s AIFA authorized warehouses operate according to these principles,thanks to a Quality system, advanced technologies and validated procedures that control every phase of the supply chain, from the receipt of the API in storage to its shipment, ensuring full traceability and continuous control of batches for pharmaceutical companies.